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Abstract 
Background: Atherosclerosis (AS) presents characteristic of a chronic inflammatory disease in which both adaptive 
and innate immune cells play roles. Accumulating evidence has showed the impairment of natural killer (NK) cells 
in atherosclerosis, however, the mechanisms of this impairment remain unclear. In this study, we investigated the 
expression of CD160 on NK cells and assessed its pathological roles in NK loss during atherogenesis.
Methods: CD160 expression on NK cells was measured in 49 AS patients and 41 healthy controls (HC) by flow 
cytometry, their inflammatory cytokine levels in sera were determined by ELSIA, and the effect of CD160 engagement 
on NK cells was evaluated by in vitro culture experiments.
Results: Compared to HC, AS patients had a significantly increased CD160 expression on peripheral NK cells and  
concomitantly decreased peripheral NK cell number, and increased CD160 expression was positively related to the 
levels of serum lipids and IFN-γ, TNF-α and IL-6 inflammation cytokines, which all are risk factors for atherogenesis, and 
inversely correlated with peripheral NK cell number. Furthermore, engagement of CD160 receptor on NK cells from 
AS patients triggers a significantly increased production of inflammation cytokines and subsequent NK cell apopto-
sis, and blockade of TNF-α prevented the increased apoptosis of NK cells from AS patients after CD160 engagement, 
indicating a critical role of TNF-α in mediating NK cell loss by CD160 engagement.
Results: Our results provide evidence that elevated CD160 expression on NK cells plays an important role in NK 
cell loss in atherosclerosis. The increased CD160 expression on NK cells might be used as an indicator for disease 
progression.
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Background
Atherosclerosis (AS) is a chronic inflammatory disease 
of elastic and large muscular arteries, characterized by 
lesions containing cholesterol, immune cells, smooth 
muscle cells, and necrotic cores [1]. A key component of 
atherosclerotic plaque inflammation is the presence of 
different innate immune cell types including mast cells, 
neutrophils, natural killer cells, monocytes, macrophages 
and dendritic cells [2, 3]. NK cells are bone marrow-
derived innate immune cells that sense pathological 
changes in tissues through the balanced cognate activities 
of inhibitory and activating receptors, which respectively 
recognize the reduced expression of major histocompati-
bility complex (MHC) class I molecules and the increased 
expression of MHC class I homologues such as MICA 
and MICB on affected cells [4]. These cells have been 
detected in human and mouse atherosclerotic lesions 
where they frequently localized to regions near necrotic 
cores deep within plaques and also in shoulder regions 
[5–11]. However, the role of NK cells in atherosclerosis 
is still unclear.
Early studies using beige-mutant mice on the back-
ground of low density lipoprotein (LDL) receptor (LDLR) 
deficiency (LDLR−/−) suggested a protective role for NK 
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cells in atherosclerosis that is independent of NK cell-
mediated cytolysis [7]. Subsequently, it was shown that 
deficiency of functional NK cells significantly reduced 
the size of atherosclerosis in Ly49A transgenic mice, sug-
gesting a proatherogenic property for NK cells in athero-
sclerosis development [8]. These conflicting results may 
be partially explained by the fact that beige mutation or 
Ly49A transgene also influences the functions of other 
immune cells [11–14], making it difficult to clearly define 
the role of NK cells in the pathogenesis of atherosclerosis. 
Recently, by depleting or repleting NK cells in atheroscle-
rosis-prone ApoE-deficient (ApoE−/−) mice, Selathurai 
et al. showed that NK cells promote atherosclerosis in a 
cytotoxicity-dependent manner [11]. Despite these stud-
ies, it remains to explore the detailed molecular mecha-
nisms for the involvement of NK cells in atherosclerosis.
CD160 is a glycosylphosphatidylinositol (GPI)-anchored 
member of the immunoglobulin superfamily expressed 
on the majority of circulating NK cells which correspond 
to the nonproliferating, highly cytolytic, CD56dimCD16+ 
subset [15, 16]. CD160 engagement by both classical and 
non-classical MHC-I molecules mediates NK cell cyto-
toxicity and proinflammatory cytokine production of a 
unique profile (IFN-γ, TNF-α, and IL-6) [17–19], all of 
which have been implicated in atherosclerosis [20–22]. 
In addition, CD160 has been also described capable of 
binding with herpes virus entry mediator (HVEM) to 
augment inflammatory cytokine production and cyto-
lytic function of NK cell [23], indicating a critical role 
of CD160 in regulating NK cell functions. The findings 
have motivated us to test the hypothesis that CD160 is 
involved in NK cell functioning in atherosclerosis.
Methods
Study subjects
This research was carried out in line with the tenets of the 
Declaration of Helsinki and was approved by the Institu-
tion Review Board of the Navy General Hospital of Chi-
nese PLA. A total of 49 AS patients, including 19 patients 
with stable angina pectoris (SAP) and 30 with unstable 
angina pectoris (UAP), were recruited at Department of 
Cardiology of Navy General Hospital of PLA from Octo-
ber 2012 to June 2013. Forty-one sex and age-matched 
healthy subjects served as controls (Table  1). Coronary 
artery atherosclerosis was documented angiographically 
in all patients. None of the subjects had received immu-
nomodulatory treatment during the 1-month period 
before sampling. Written informed consent was obtained 
from each participant. All samples were analyzed by flow 
cytometry with a Cytomics FC500 (Beckman Coulter). 
Sera were isolated from all study subjects and then ana-
lyzed for the concentrations of triglyceride (TG), choles-
terol (Cho) and IFN-γ, TNF-α and IL-6 cytokines.
Flow cytometry
Blood samples were mixed with 2 mL of ACK lysis buffer 
and incubated for 10 min to deplete red blood cells; after 
that, cells were incubated with human Fc receptor block-
ing buffer (eBioscience) at 4°C for 10 min followed by the 
incubation with specific antibodies or isotype-matched 
controls at 4°C for 30 min at the manufacturers’ recom-
mended concentrations. PECY7-conjugated anti-human 
CD3, FITC-conjugated anti-human CD8, PECY5-con-
jugated anti-human CD56, PE-conjugated mouse IgM 
isotype control and PE-conjugated anti-human CD160 
(Clone BY55; all from BD Biosciences) were used for flow 
cytometry analysis. Samples were washed with FACS 
buffer (2% BSA in PBS, 0.09% sodium azide). Pellets were 
resuspended in 300  mL of FACS buffer. Samples were 
acquired on a Cytomics FC 500 MPL (Beckmam Coul-
ter) and analyzed by FlowJo software (TreeStar, Inc.) as 
reported previously [24].
Determination of serum lipids and cytokines
Serum total Cho and TG were routinely measured in the 
Laboratory Department of the General Hospital of peo-
ple’s Liberation Army by enzymatic methods with a com-
mercial kit (CHOD-PAP, Boehringer-Mannheim GmbH, 
and Konelab TRIGLYCERIDES, Thermo Electron Co.). 
Serum concentrations of IFN-γ, TNF-α and IL-6 were 
measured by using enzyme-linked immunosorbent assay 
(ELISA) kits from R&D systems according to manufac-
turer’s instructions.
Preparation of purified NK cells
CD3−CD56+ NK cells were obtained from PBMCs of 5 
UAP patients and 5 HC using MoFlo™ XDP cell sorting sys-
tem (Beckmam Coulter) as reported previously [24]. The 
Table 1 Clinical characteristics of enrolled subjects
Data were expressed as median ± SD.
Patients with atherosclerosis (AS); patients with stable angina pectoris (SAP); 
patients with unstable angina pectoris (UAP); HC (HC); cholesterol (Cho); triglyc-
eride (TG); high density lipoprotein cholesterol (HDL-C); low density lipoprotein 
cholesterol (HDL-C); systolic blood pressure (SBP); diastolic blood pressure (DBP). 
M, male; F, female.
Subjects HC (n = 41) AS
SAP (n = 19) UAP (n = 30)
Age 55.43 ± 19.54 56.46 ± 21.54 57.16 ± 18.54
Gender (M/F) 28/13 12/7 19/11
Cho (mM) 4.34 ± 1.63 4.25 ± 1.47 4.76 ± 1.51
TG (mM) 1.05 ± 0.63 1.59 ± 0.93 1.71 ± 1.03
HDL-C (mM) – 1.29 ± 0.43 1.11 ± 0.33
LDL-C (mM) – 2.81 ± 1.16 3.11 ± 1.23
SBP (mmHg) 116.6 ± 9.5 123.6 ± 10.5 133.6 ± 14.5
DBP (mmHg) 68.6 ± 7.7 75.6 ± 8.7 78.5 ± 9.2
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purity of the isolated NK cells was >98% as determined by 
flow cytometry (Additional file 1: Figure: S1). Cells were 
subsequently cultured at a concentration of 2 × 106 cells/ml 
in duplicate 24-well plates in RPMI 1640 medium (Hyclone) 
with 10% FBS and 100 U/mL rhIL-2 (R&D systems).
CD160 engagement by specific monoclonal  
antibody (mAb)
Engagement of CD160 receptor on NK cells from AS 
patients or HC cultured in 24-well plates was conducted 
by using anti-CD160 agonistic mAb (Clone CL1-R2; 
MBL International) at the final concentration of 1–10 µg/
ml for 16 h at 37°C in 5% CO2. IgG1 isotype control was 
also used at the same conditions. rhIL-2 (100  U/ml) was 
added during the incubation time. Supernatants were col-
lected and stored at −80°C until further analysis. In some 
experiments, engagement of CD160 receptor on NK cells 
by anti-CD160 agonistic mAb were performed in the pres-
ence of 1 or 10 µg/mL control or TNF-α-neutralizing mAb 
(Clone 28401, mouse IgG1; from R&D systems), and then 
NK cells were subjected to apoptosis analysis by Annexin 
V/7-aminoactinomycin D staining 48, 72 and 96 h later.
Annexin V and 7‑aminoactinomycin D (7‑AAD) staining
The determination of apoptotic cells was performed 
per manufacturer’s instruction (R&D systems). Briefly, 
treated cells were washed twice in cold PBS and resus-
pended in Annexin V-binding buffer at a concentration 
of 3 × 106 per ml. This suspension (100 μl) was stained 
with 5 μl of Annexin V-FITC and 5 μl 7-AAD. The cells 
were gently vortexed and incubated for 15 min at room 
temperature in the dark. After addition of 400  μl of 
binding buffer to each tube, cells were analyzed by flow 
cytometry immediately.
Statistics
Results were expressed as mean ± SD. All statistical anal-
yses were performed using GraphPad Prism 5. Two-tailed 
unpaired student’s t test was used to compare the statisti-
cal difference between two groups and one-way ANOVA 
followed by Tukey’s multiple comparisons test was used to 
compare three or more groups. The Spearman correlation 
analysis was used to calculate the correlation coefficient. 
A P value <0.05 was considered as statistically significant.
Results
Increased CD160 expression on NK cells from AS patients
To explore the potential involvement of CD160 in athero-
genesis, we first compared CD160 expression levels in AS 
patients and the HC. Flow cytometric analysis detected a 
low level of CD160 expression on both CD3+CD8+ and 
CD3+CD8− (most CD4+) T cells as previously reported 
[25]; however, no difference in the percentage and mean 
fluorescence intensity (MFI) of CD160 expression within 
these cells was observed between the AS patients and HC 
(Figure  1b; Additional file 2: Figures  S2A, S1B). A rep-
resentative donor analysis is shown in Figure  1a. Unex-
pectedly, CD160 expression (percentage and MFI) on 
CD3−CD56+ NK cells from patients with AS was signifi-
cantly higher than that from HC (Figure  2b; Additional 
file 2: Figure  S2C). A representative donor analysis is 
shown in Figure 2a. The increased CD160 expression was 
especially prominent on NK cells from patients with UAP 
(Figure 2c), suggesting a probability of CD160 expression 
on NK cells as a potential indicator of disease progres-
sion. Furthermore, we observed a significant correlation 
between the CD160 expression on NK cells and serum 
TG and Cho (Figure 2d), which are etiological and aggra-
vating factors of atherogenesis [26–28].
In accordance with the nature of atherosclerosis as 
a chronic inflammatory disease [1, 29], the levels of 
plasma IFN-γ, TNF-α and IL-6, three major inflam-
matory biomarkers, were significantly increased in AS 
patients compared with those in healthy subjects (Fig-
ure  3a). Importantly, there was a positive correlation 
between the CD160 expression on CD3−CD56+ NK cells 
and the plasma level of these biomarkers in AS patients 
(Figure  3b). No correlation was seen in HC population 
(Additional file 3: Figure 3A–C). This result is also con-
sistent with the finding that the expression of CD160 
on NK cells from UAP patients was significantly higher 
than those in SAP patients (Figure 2c), further support-
ing the hypothesis that UAP patients suffer from more 
severe inflammation than SAP patients [19, 20]. Mul-
tivariate regression analysis further suggested a pos-
sible independent role of CD160 in predicting disease 
progression, but this was not statistically significant 
(p  =  0.068), which might have been due to the small 
number of studied subject. In summary, our results 
demonstrate increased expression of CD160 on NK cells 
from patients with atherosclerosis, which might indicate 
disease progression.
CD160 expression correlates with the reduced NK cell 
number among PBMCs in patients with AS
As previously reported [10, 30, 31], we found reduced 
NK cell number in the blood from patients with AS com-
pared with the HC (Figure 4a). Further analysis showed 
that the reduction of peripheral NK cell count was sig-
nificantly prominent in patients with UAP than that in 
patients with SAP (Figure  4b). In addition, a significant 
inverse correlation between the level of CD160 expres-
sion and the number of NK cells was observed in all AS 
patients (Figure 4c) and, in particular, in the subgroup of 
UAP patients (Figure 4d). No correlation was seen in HC 
population (Additional file 3: Figure S3d).
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Figure 1 Expression levels of CD160 on CD4+ T and CD8+ T cells in AS patients. Blood samples were collected to detect CD160 expression 
levels on both CD3+CD8+ and CD3+CD8− (most CD4+) T cells by flow cytometry. a Representative dot plots and histograms of CD160 expres-
sion on CD3+CD8− (most CD4+) and CD3+CD8+ T cells from HC (upper panels) and AS patients (bottom panels). b The percentages of circulating 
CD160+CD3+CD8− T cells (upper graph) and CD160+CD3+CD8+ T cells (bottom graph) in HC and AS patients with each dot representing one 
subject. Data are expressed as mean ± SD. Student t test (b).
Figure 2 Increased expression of CD160 on NK cells in AS patients. Blood samples were collected to detect CD160 expression on NK cells by flow 
cytometry. a Representative dot plots and histograms of CD160 expression on CD3−CD56+ NK cells from HC (upper panels) and AS patients (bottom 
panels). b The percentage of circulating CD160+ NK cells compared between the AS patients and HC. c The percentage of circulating CD160+ NK 
cells compared among UAP patients, SAP patients and HC. d The correlation between the percentage of circulating CD160+ NK cells and serum TG 
and Cho concentrations in AS patients. Data are expressed as mean ± SD. Student t test (b), one-way ANOVA (c) and spearman correlation test (d).
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CD160 engagement induces TNF‑α production which 
triggers NK cell apoptosis
To probe the potential role of increased CD160 expres-
sion on NK cells from patients with AS, we isolated NK 
cells from AS patients and HC and then subjected them 
to CD160 engagement by an agonistic anti-CD160 mAb. 
Consistent with the proinflammatory role of CD160 and 
its increased expression in AS patients, we detected a 
Figure 3 CD160 expression on circulating NK cells correlates with serum levels of inflammatory cytokines in AS patients. a Serum concentrations 
of IFN-γ, TNF-α and IL-6 determined by ELSIA. b The correlation analysis between the percentage of circulating CD160+ NK cells and serum levels of 
IFN-γ, TNF-α and IL-6. Data are expressed as mean ± SD. Student t test (a) and spearman correlation test (b).
Figure 4 CD160 expression on NK cells is negatively correlated with peripheral NK cell number in patients with AS. a, b The percentage of NK 
cells among PBMCs in all AS patients (a) or in SAP and UAP patients (b). c, d The correlation between the percentage of circulating NK cells and the 
levels of CD160 expression on NK cells in all AS patients (c), including SAP (square) and UAP (triangle) patients, and in only UAP patients (d). Data are 
expressed as mean ± SD. Student t test (a), one-way ANOVA (b) and spearman correlation test (c, d).
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significantly increased production of proinflammatory 
cytokines, including IFN-γ, TNF-α and IL-6, from NK 
cells of AS patients as compared to that from HC (Fig-
ure 5a). To further explore whether CD160 engagement 
would lead to NK cell death, we applied AnnexinV/7-
AAD double staining to dissect the apoptosis of NK cells 
at several time points after CD160 engagement. Notably, 
we observed a significantly increased apoptosis of NK 
cells from AS patients compared to that from HC at all 
evaluable time points with difference being more pro-
nounced along time (Figure 5c). The representative dot-
plots were shown in Figure 5b.
Figure 5 CD160 engagement triggers secretion of inflammatory cytokines and subsequent NK cell death. a Engagement of CD160 receptor on 
NK cells from AS patients (n = 5) and HC (n = 5) was conducted by using an anti-CD160 agonistic mAb at serial concentrations indicated in figures. 
Treatments with medium and IgG1 isotype control were used as controls. Sixteen hours later, supernatants were collected and assayed for the pro-
duction of IFN-γ, TNF-α and IL-6. b, c NK cells from AS patients and HC were treated as above and their apoptosis was determined by Annexin V/7-
AAD staining 48, 72 and 96 h later with apoptotic cells defined as Annexin V+ cells (c). The representative dot plots were shown in b. d Engagement 
of CD160 receptor on NK cells from AS patients were performed in the presence of control (10 µg/ml) or TNF-α-neutralizing (1 and 10 µg/ml) mAb 
and their apoptosis was determined by Annexin V/7-AAD staining 96 h later. Untreated NK cells from AS patients (UNT, no CD160 engagement) and 
treated NK cells from HC (CD160 engagement without neutralizing mAb) were used as controls. e The correlation of serum TNF-α with the percent-
age of NK cells in PBMCs with each dot presenting one subject. In these experiments, the purity of NK cells we used was >95% as determined by 
flow cytometry (Additional file 1: Figure S1). Data are expressed as mean ± SD of five AS patients and HC with each case triplicates (a) or representa-
tive of two independent experiments (c, d). *p < 0.05, **p < 0.01, student t test (a, c, d) and spearman correlation test (e).
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As TNF-α, an important proatherogenic factor [29], 
has been reported to induce NK cell apoptosis [32], it 
is reasoned that increased TNF-α production by NK 
cells from AS patients after CD160 engagement may be 
responsible for their increased apoptosis. To test this 
hypothesis, we treated NK cells from AS patients with 
agonistic anti-CD160 mAb in the presence of control 
or TNF-α-neutralizing antibody to see if the increased 
apoptosis of NK cells from AS patients triggered by 
CD160 engagement could be reversed by blocking TNF-α 
activity. As shown in Figure 5d, blockade of TNF-α activ-
ity decreased CD160 engagement-induced apoptosis of 
NK cells from AS patients to the level that achieved by 
NK cells from HC, suggesting a critical role of TNF-α 
in engendering cell death of NK cells from AS patients 
after CD160 engagement. In addition, we found a reverse 
correlation between serum TNF-α concentration and 
circulating NK cell number, further supporting a role of 
TNF-α in NK cell loss in AS patients (Figure 5e).
Discussion
Here, for the first time, we demonstrate increased CD160 
expression on circulating NK cells and a critical role 
of CD160 in triggering inflammatory cytokine secre-
tion and its subsequent apoptosis of NK cells during 
atherogenesis.
The increased CD160 expression on NK cells might 
be associated with an inflamed status in AS, which is 
supported by the following three points. First, CD160 
expression on NK cells positively correlated with the 
levels of serum IFN-γ, TNF-α and IL-6, three important 
inflammation markers [29]; CD160 engagement further 
induces the secretion of these inflammatory cytokines, 
constituting a positive feedback loop to promote the 
inflammation. Second, CD160 expression on NK cells of 
UAP patients, who suffer from more severe inflamma-
tion, was significantly higher than that of SAP patients. 
Third, the increased CD160 expression on NK cells posi-
tively correlated with high levels of serum lipids, which 
can lead to higher levels of inflammation. The data sug-
gest a close relationship between CD160 expression 
on NK cells and inflammation and the potential use of 
CD160 as an indicator for the progression of AS. Cur-
rently, the mechanisms for increased CD160 expression 
on NK cells in AS patients remain elusive; it is very likely 
that elevated CD160 on NK cells results from adaption 
of NK cells to the persistent inflamed microenviron-
ment within the bodies of AS patients where multiple 
inflammatory mediators might induce or upregulate the 
transcription and/or expression of CD160 by the yet-to-
identified mechanisms. Future studies are warranted to 
explore the detailed molecular mechanisms. In addition, 
CD160 transmembrane isoform (CD160-TM) has been 
reported to be selectively expressed by activated NK cells 
[33], however, the antibody we applied to detect CD160 
expression cannot reliably recognize the CD160-TM 
[25] and the antibodies distinguishing CD160-GPI from 
CD160-TM are also not available, therefore, further stud-
ies are needed to concomitantly investigate the expres-
sion changes of two forms of CD160 when suitable agents 
are available.
Reduced NK cell number with compromised NK cell 
functions has been iteratively reported in AS patients [10, 
30, 31], for which the mechanisms are still poorly under-
stood. Our demonstration that engagement of CD160 on 
NK cells from AS patients triggered a significant produc-
tion of inflammatory cytokines and subsequently NK cell 
death may partially explain the decreased NK cell num-
ber seen in AS patients. Previous studies have shown that 
combined cytokine priming, such as IL-2/IL-12 or IL-15/
IL-12 stimulation, induces apoptosis of NK cells at the 
late stage, which can be partially prevented by TNF-α 
blockade [32]. Consistent with their findings, we found 
that neutralization of TNF-α completely prevented the 
increased apoptosis of NK cells from AS patients induced 
by CD160 engagement, suggesting a critical role of 
TNF-α in mediating NK cell death from CD160 engage-
ment, which is further supported by our observation 
that serum concentration of TNF-α negatively correlated 
with quantity of NK cells in AS patients. Certainly, more 
in vitro functional assays with a bigger sample size are 
needed to exactly define the role of CD160 engagement 
in inflammatory cytokine production and subsequent NK 
cell loss.
In our study, we used an agonistic mAb to engage 
CD160 receptor on NK cells, however, it remains unclear 
the identity of molecules engaging CD160 in vivo. Previ-
ous studies showed that soluble HLA class I can induce 
NK cell apoptosis by the engagement of killer-activat-
ing HLA class I receptors or CD8 molecule through 
FasL–Fas interaction [34, 35]; as HLA class I molecules 
(HLA-C or HLA-G1) have been identified to be physio-
logical ligands for CD160 [18, 36], it is likely that engage-
ment of CD160 receptor by physiological HLA class I 
molecules expressed on cells reciprocally interacting with 
NK cells can trigger inflammatory cytokine production 
and subsequent apoptosis of NK cells. Further examin-
ing the localization of CD160 and its ligands by in situ 
immunofluorescence staining of tissue samples from AS 
patients would be helpful to clarify this issue.
The presence and function of NK cells in athero-
sclerosis development has been demonstrated both in 
human autopsy specimens and in various mouse mod-
els, however, the precise role and action mode of NK 
cells in human atherosclerosis has yet to be clarified, 
and the same is the exact role of CD160 on NK cells in 
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atherosclerosis in vivo. In addition to increasing inflam-
matory cytokines, it is possible that elevated CD160 
expression by NK cells from AS patients could increase 
their cytotoxic activity, contributing to increased col-
lateral damages and associated inflammation in ath-
erosclerotic sites since CD160 engagement by HVEM 
and MHC-I molecules has been described enhance the 
cytotoxicity of NK cells [17, 18, 23]. Due to small blood 
samples, we did not examine the cytotoxic activity of 
NK cells from AS patients, and recent study conducted 
in CD160-deficent mice demonstrates that CD160 con-
trols the IFN-γ production of NK cells without affecting 
their cytotoxicity in tumor models [37], suggesting that 
CD160 on NK cells can intensify the inflammation inde-
pendent of NK’s cytotoxicity. Thus, future studies are 
needed to figure out which effector arm derived from 
CD160 engagement predominately contributes to the 
atherogenesis.
Conclusions
CD160 expression on NK cells from patients with AS 
is increased significantly, which might be associated 
with the inflamed microenvironment in AS. In turn, the 
increased CD160 expression plays a role in inflammation 
maintenance and NK loss by promoting inflammatory 
cytokine production and subsequent NK apoptosis dur-
ing atherogenesis. However, the mechanisms for CD160 
induction and the exact role of CD160 in atherosclerosis 
are not clear and need to be further investigated, espe-
cially with animal models. Our data suggest that CD160 
might be used as a potential indicator for atherosclerosis 
progression.
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